ArticlePregnancy (Hoboken, N.J.)2025
The association between prenatal depression and persistent postpartum pharmaceutical opioid use in six US states.
Article in Pregnancy (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antenatal Opioid Exposure and Cerebral Cortical Maturation in Newborns.JAMA network open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Opioids are commonly prescribed to manage postpartum pain. Yet, 1.7%-2.2% of postpartum people develop new persistent use of opioids after receiving a postpartum opioid prescription. Individuals who experience opioid misuse often have mental health comorbidities. A common mental health condition among pregnant individuals is depression. Information about the association between prenatal depression and persistent opioid use postpartum could guide shared decision-making during counseling, but most available studies rely on insurance claims data, which do not capture non-prescribed opioids. In this study, we examined the association between prenatal depression and persistent postpartum opioid use in selected US states. Methods: We used data from the 2019 Pregnancy Risk Assessment Monitoring System (PRAMS) Core Questionnaire, Opioid Supplement, and Opioid Call Back Survey from six states (Kentucky, Louisiana, Massachusetts, Missouri, Pennsylvania, and Utah) to examine the association between prenatal depression and persistent postpartum opioid use (defined as postpartum opioid use for 4 weeks or more) in the United States. The survey captured postpartum use of pharmaceutical opioids, including those prescribed to the respondent and those prescribed to another individual. Unadjusted and adjusted logistic regression models were used to assess the association among postpartum individuals. We calculated marginal effects and presented the study results as percentage point differences with 95% CIs. All models used PRAMS survey weights. Results: A total of 1680 individuals were included in the study, corresponding to 154,878 birthing people in the United States. Of these individuals, the prevalence of prenatal depression was 18.2%. Among those with prenatal depression, 12.3% (95% CI: 7.3, 20.1) of individuals had persistent postpartum opioid use compared to 3.3% (95% CI: 2.3, 4.7) among individuals without prenatal depression ( Conclusion: Individuals with depression during pregnancy were more likely to develop persistent postpartum opioid use. Recognizing the relationship between prenatal depression and persistent postpartum opioid use may help tailor postpartum pain management and counseling strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.